Important Information for Intellia Therapeutics Securities Holders: Rosen Law Firm Announces Class Action Lawsuit and Lead Plaintiff Deadline
Rosen Law Firm, a leading global investor rights law firm, reminds purchasers of Intellia Therapeutics, Inc. (NASDAQ: NTLA) securities between July 30, 2024, and January 8, 2025 (the “Class Period”), of the important deadlines in a class action lawsuit. The lawsuit alleges that Intellia Therapeutics and certain of its officers and directors made materially false and misleading statements and failed to disclose material information.
What Happened?
According to the lawsuit, the defendants made false and/or misleading statements and/or failed to disclose that:
- Intellia Therapeutics was experiencing manufacturing challenges with its CRISPR-Cas9 gene editing platform;
- The company’s lead CRISPR-Cas9 product candidate, NTLA-2001, would not be approved by the U.S. Food and Drug Administration (“FDA”) in its current form;
- There were delays in the development of Intellia Therapeutics’ pipeline;
- As a result, Intellia Therapeutics’ financial statements were materially false and misleading at all relevant times.
What Should Investors Do?
If you purchased Intellia securities during the Class Period, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. The lead plaintiff deadline is April 14, 2025. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2025. To opt out of this class action, or to obtain more information, contact the Rosen Law Firm.
How Will This Affect Me?
If you purchased Intellia securities during the Class Period, this lawsuit may entitle you to compensation. However, it is important to note that every case is unique and past results do not guarantee future outcomes. If you are unsure about your options or have questions about your rights as an investor, it is advisable to contact a securities attorney.
How Will This Affect the World?
The outcome of this lawsuit may have implications for the biotechnology industry and the broader investment community. It could potentially lead to increased scrutiny of companies in the gene editing space and heightened awareness of the importance of transparency and accurate disclosures. However, it is important to remember that the outcome of any individual lawsuit does not necessarily reflect broader trends or market conditions.
Conclusion
If you purchased Intellia Therapeutics securities between July 30, 2024, and January 8, 2025, and believe that you may have been affected by the alleged false and misleading statements, you may be entitled to compensation. The lead plaintiff deadline is April 14, 2025. It is advisable to consult with a securities attorney to understand your options and protect your investor rights.
The Rosen Law Firm encourages investors to carefully monitor the company’s developments and any corresponding legislative or regulatory changes that may affect the company’s business operations. The firm reminds investors that it is committed to ensuring that all investors have the opportunity to exercise their rights under the law.
This notice does not constitute an offer or solicitation of services or an admission of representation. It is for informational purposes only and is not intended as legal or investment advice on any particular matter, nor does it form an attorney-client relationship.
